New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease Paris, February ...

Sanofi has added another string to its Pompe disease therapy bow, after getting FDA approval for Nexviazyme, its latest therapy for the rare, inherited disorder. The US regulator has approved ...

Sanofi’s Nexviazyme (Nexviadyme in Europe) is also an engineered version of GAA, but designed in a way to improve the enzyme’s ability to clear glycogen. Nexviazyme was approved by the FDA in ...

New data suggest treatment with Nexviazyme (avalglucosidase alfa) meaningfully improved ptosis, or drooping eyelid, in paediatric patients with infantile-onset Pompe disease (IOPD) over nearly three ...

New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease Paris, February ...

Sanofi has added another string to its Pompe disease therapy bow, after getting FDA approval for Nexviazyme, its latest therapy for the rare, inherited disorder. The US regulator has approved ...

Paris, February 24, 2023. Today, at WORLDSymposium TM, data from the Phase 3 COMET study long-term extension showed sustained treatment effect of Nexviazyme ® (avalglucosidase alfa) over nearly three ...

New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease Paris, February 24, ...

New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease Paris, February ...